Is Barinthus Biotherapeutics plc. (BRNS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 48.8% / 30% | 449.5% / 30% | 52.8% / 30% | 17.89% / 5% | ✗ NOT HALAL |
| DJIM | 48.8% / 33% | 449.5% / 33% | 52.8% / 33% | 17.89% / 5% | ✗ NOT HALAL |
| MSCI | 7.5% / 33% | 69.0% / 33% | 8.1% / 33% | 17.89% / 5% | ✗ NOT HALAL |
| S&P | 48.8% / 33% | 449.5% / 33% | 52.8% / 33% | 17.89% / 5% | ✗ NOT HALAL |
| FTSE | 7.5% / 33% | 69.0% / 33% | 8.1% / 50% | 17.89% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -65.0% | |
| Return on Assets (ROA) | -28.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$29M |
| Free Cash Flow | -$30M |
| Total Debt | $12M |
| Debt-to-Equity | 15.2 |
| Current Ratio | 7.8 |
| Total Assets | $160M |
Price & Trading
| Last Close | $0.55 |
| 50-Day MA | $0.65 |
| 200-Day MA | $0.97 |
| Avg Volume | 48K |
| Beta | -0.6 |
|
52-Week Range
$0.51
| |
About Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Barinthus Biotherapeutics plc. (BRNS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Barinthus Biotherapeutics plc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Barinthus Biotherapeutics plc.'s debt ratio?
Barinthus Biotherapeutics plc.'s debt ratio is 48.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.5%.
What are Barinthus Biotherapeutics plc.'s key financial metrics?
Barinthus Biotherapeutics plc. has a market capitalization of $22M, and revenue of $15M. Return on equity stands at -65.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.